Evaluating the Effectiveness of Thai Basil Extract in Managing Type 2 Diabetes
DOI:
Abstract
This study investigated the potential of Ocimum basilicum var. thyrsiflora (Thai basil) extract as a natural adjunct therapy for the management of type 2 diabetes. The increasing prevalence of diabetes globally and the limitations of conventional therapies require alternative approaches, especially in regions where Thai basil is culturally accepted. The objective was to evaluate the effects of Thai basil on blood glucose levels and glycemic control in patients with type 2 diabetes. A randomized controlled trial was conducted in 2024 with 200 participants, aged 30–65 years, diagnosed with type 2 diabetes. Participants were assigned to either the Thai basil extract group (500 mg daily) or the placebo group, with clinical data collected at baseline, mid-intervention, and post-intervention. Findings showed that the intervention group experienced significant reductions in fasting blood glucose and HbA1c levels, indicating improved long-term glycemic control. In addition, lipid profiles, including cholesterol and triglyceride levels, were positively affected. However, no significant weight loss was observed. This review highlights the therapeutic potential of Thai basil bioactive compounds, including flavonoids and essential oils, which have antioxidant, anti-inflammatory, and antidiabetic properties. Limitations such as sample size and study duration are noted, indicating the need for further studies with larger, more diverse populations and longer duration. Future studies should explore the optimal dosage, formulation, and long-term effects of Thai basil. This study supports the inclusion of Thai basil in diabetes care, especially in regions where basil is widely available and culturally accepted.
Downloads
Views : 477
Downloads : 198
References
M. Villalva, et al, “Antioxidant, anti-inflammatory, and antibacterial properties of an Achillea millefolium L. extract and its fractions obtained by supercritical anti-solvent fractionation against Helicobacter pylori,” Antioxidants (Basel), vol. 11, no. 10, 2022.
A. Prasopthum, T. Insawek, and P. Pouyfung, “Herbal medicine use in Thai patients with type 2 diabetes mellitus and its association with glycemic control: A cross-sectional evaluation,” Heliyon, vol. 8, no. 10, 2022.
M. J. Davies, et al, “Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 45, no. 11, pp. 2753–2786, 2022.
T. Saelao, et al, “Analysis of antioxidant capacity variation among Thai Holy Basil cultivars (Ocimum tenuiflorum L.) using density-based clustering algorithm,” Horticulturae, vol. 9, no. 10, 2023.
N. Tran, B. Pham, and L. Le, “Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery,” Biology (Basel), vol. 9, no. 9, p. 252, Aug. 2020
N. S. Azizah, et al, “Sweet basil (Ocimum basilicum L.) - A review of its botany, phytochemistry, pharmacological activities, and biotechnological development,” Plants (Basel), vol. 12, no. 24, 2023.
G. Zengin, et al, “Phytochemical profile and biological activities of different extracts of three parts of Paliurus spina-christi: A linkage between structure and ability,” Antioxidants (Basel), vol. 12, no. 2, 2023.
A. Abusaliya, et al, “Glycosidic flavonoids and their potential applications in cancer research: A review,” Molecular & Cellular Toxicology, vol. 18, pp. 9-16, 2022.
M. Wolosowicz, S. Prokopiuk, and T. W. Kaminski, “Recent advances in the treatment of insulin resistance targeting molecular and metabolic pathways: Fighting a losing battle?” Medicina (Kaunas), vol. 58, no. 4, 2022.
J. Y. Kim and N. H. Kim, “Initial Combination Therapy in Type 2 Diabetes,” Endocrinology and Metabolism, vol. 39, no. 1, pp. 23-32, 2024.
N. Abdelrahman, et al, “Hypoglycemic efficacy of Rosmarinus officinalis and/or Ocimum basilicum leaves powder as a promising clinico-nutritional management tool for diabetes mellitus in Rottweiler dogs,” Veterinary World, vol. 13, no. 1, 2020.
N. A. ElSayed, et al., “6. Glycemic targets: standards of care in diabetes-2023,” Diabetes Care, vol. 46, no. 1, 2023.
M. M. Ayyash, et al., “Characterization of new probiotics from dairy and non-dairy products - Insights into acid tolerance, bile metabolism and tolerance and adhesion capability,” J. Dairy Sci., vol. 104, no. 8, 2021.
J. B. Adokwe, D. Waeyeng, K. Suwan, K. Camsanit, C. Kaiduong, P. Nuanrat, P. Pouyfung, S. Yimthiang, J. Petchoo, S. Satarug, and T. Khamphaya, “Plant-based diet and glycemic control in type 2 diabetes: Evidence from a Thai health-promoting hospital,” Nutrients, vol. 16, no. 5, 2024.
B. K. Sapkota, K. Khadayat, K. Sharma, B. K. Raut, D. Aryal, B. B. Thapa, N. Parajuli, “Phytochemical analysis and antioxidant and antidiabetic activities of extracts from Bergenia ciliata, Mimosa pudica, and Phyllanthus emblica,” Adv. Pharmacol. Pharm. Sci., vol. 2022.
H. Kashtoh and K. H. Baek, “New insights into the latest advancement in α-amylase inhibitors of plant origin with anti-diabetic effects,” Plants (Basel), vol. 12, no. 16, 2023.
A. Qasem, et al, “Determination of chemical composition and investigation of biological activities of Ocimum basilicum L.,” Molecules, vol. 28, no. 2, 2023.
T. Tangpao, et al, “Volatile organic compounds from basil essential oils: Plant taxonomy, biological activities, and their applications in tropical fruit productions,” Horticulturae, vol. 8, no. 2, 2022.
A. P. Antony and R. Vijayan, “Bioactive peptides as potential nutraceuticals for diabetes therapy: A comprehensive review,” Int. J. Mol. Sci., vol. 22, no. 16, 2021.
N. S. Azizah, et al, “Sweet basil (Ocimum basilicum L.) - A review of its botany, phytochemistry, pharmacological activities, and biotechnological development,” Plants, vol. 12, no. 24, 2023.
B. Martín-Carro, J. Donate-Correa, et al., “Experimental models to study diabetes mellitus and its complications: limitations and new opportunities,” Int. J. Mol. Sci., vol. 24, no. 12, 2023.
